NAD+ (nicotinamide adenine dinucleotide) is one of the most studied molecules in modern cell biology — a coenzyme that sits at the centre of how cells extract, carry, and spend energy. It is not a peptide; it is a dinucleotide built from two nucleotides joined through their phosphate groups, and it functions as an electron carrier and an enzyme cofactor rather than as a chain of amino acids. In research settings, NAD+ has become a focal point for work on metabolism, mitochondrial function, DNA repair, and the biology of ageing. This article explains what NAD+ actually is, the enzyme systems that consume it, why its decline with age is such an active research theme, and how research-grade material is handled and verified in the laboratory.
Everything below is written for laboratory and educational contexts. Alluvia Peptides supplies NAD+ for research use only — not for human or animal consumption — and stocks it within the broader longevity and metabolic-research catalogue alongside true peptides.
The full chemical name nicotinamide adenine dinucleotide tells you most of what you need to know about its structure. The molecule is a dinucleotide: two nucleotides linked through a pair of bridging phosphate groups. One nucleotide carries an adenine base (the same base found in ATP and DNA), and the other carries nicotinamide, the amide form of vitamin B3. Each base is attached to a ribose sugar, and those two riboses are joined by the phosphate bridge. That architecture is what defines NAD+ as a nucleotide-derived cofactor, and it is precisely why it should never be described as a peptide — peptides are short chains of amino acids linked by peptide bonds, a completely different chemical class. NAD+ contains no amino acids and no peptide bonds.
The "+" in NAD+ refers to the positive charge on the nicotinamide ring in the oxidised state. This detail matters because the chemistry of NAD+ is fundamentally about electron transfer. The nicotinamide ring can accept a pair of electrons (delivered as a hydride ion, two electrons plus one proton), and when it does, the oxidised NAD+ becomes the reduced form, NADH. The molecule therefore exists in two interconvertible states, and biologists almost always discuss them as a coupled set.
The NAD+/NADH couple is one of the central redox systems of the cell. In this partnership, NAD+ is the oxidising agent — the form that pulls electrons off metabolic intermediates — and NADH is the reduced carrier that ferries those electrons elsewhere. When a dehydrogenase enzyme strips a hydride from a substrate such as a sugar or a fatty-acid breakdown product, NAD+ accepts it and is reduced to NADH. Later, NADH gives those electrons up again, regenerating NAD+ so the cycle can continue. Because the pool of nicotinamide cofactor is finite, this continual regeneration is essential: a cell that cannot reoxidise NADH back to NAD+ quickly stalls its own metabolism.
Two features make this couple so useful to the cell. First, the redox reaction is reversible, so the same molecule can be charged and discharged thousands of times. Second, the ratio of NAD+ to NADH acts as a readout of the cell's metabolic state. A high NAD+/NADH ratio signals an oxidised, energy-demanding environment; a low ratio signals reductive, energy-rich conditions. Researchers frequently treat this ratio as a proxy for metabolic flux when studying how cells respond to nutrients, stress, or experimental interventions.
NAD+ threads through the three core stages of energy metabolism. In glycolysis, the breakdown of glucose in the cytoplasm, the enzyme glyceraldehyde-3-phosphate dehydrogenase uses NAD+ to oxidise a sugar intermediate, producing NADH. Without enough NAD+ available, glycolysis halts at this step — which is why fermentation pathways exist primarily to regenerate NAD+ when oxygen is scarce.
In the TCA cycle (also called the citric acid or Krebs cycle), which runs inside the mitochondrial matrix, several dehydrogenase reactions reduce NAD+ to NADH at each turn. These reactions capture much of the chemical energy released as acetyl groups are fully oxidised. The NADH generated here is the cycle's principal energy output, carrying electrons toward the next stage.
That next stage is oxidative phosphorylation. NADH delivers its electrons to Complex I of the electron transport chain, embedded in the inner mitochondrial membrane. As those electrons pass down the chain, protons are pumped across the membrane, and the resulting gradient drives ATP synthase to produce ATP — the cell's usable energy currency. Crucially, this hand-off regenerates NAD+, closing the loop and replenishing the pool that glycolysis and the TCA cycle depend on. In this way, NAD+ is simultaneously an input and an output of cellular respiration, and its availability is woven into nearly every energy-yielding reaction a cell performs.
For decades NAD+ was understood mainly as a redox cofactor. A more recent and rapidly expanding body of research treats it as something else as well: a consumable substrate for enzymes that cleave the molecule to drive signalling and regulatory processes. Unlike its redox role — where NAD+ is recycled intact — these reactions actually break NAD+ apart, consuming it. This is one reason the size of the cellular NAD+ pool has drawn so much attention.
Sirtuins are a family of NAD+-dependent enzymes (seven members in mammals, SIRT1 through SIRT7) that remove acetyl and other acyl groups from proteins. Each catalytic cycle consumes one molecule of NAD+, producing nicotinamide and a modified metabolite as by-products. Because their activity is tied directly to NAD+ availability, sirtuins effectively act as sensors of the cell's metabolic state — they become more active when NAD+ is plentiful. In research models, sirtuins have been linked to the regulation of gene expression, mitochondrial biogenesis, and stress-response pathways, which is why they feature so prominently in studies connecting NAD+ to cellular maintenance and ageing.
PARPs (poly-ADP-ribose polymerases) are another major NAD+-consuming family, best known for their role in the DNA-damage response. When DNA strands break, PARP enzymes detect the lesion and use NAD+ as a source of ADP-ribose units, building chains that recruit repair machinery to the damage site. This activity can be substantial: heavy DNA damage drives heavy PARP activity, which in turn draws down the NAD+ pool. Researchers have long been interested in the competition this creates — when PARPs consume large amounts of NAD+, less may be available for sirtuins and for redox metabolism, an interplay frequently examined in the context of genomic stress and ageing.
CD38 is an enzyme (and cell-surface marker) that hydrolyses NAD+ to generate calcium-signalling messengers such as cyclic ADP-ribose. It is a notably efficient consumer of NAD+, and research has highlighted CD38 as one of the principal drivers of NAD+ turnover. Of particular interest, CD38 expression has been observed to rise in aged tissues in laboratory studies, which has made it a focus for investigators trying to understand why NAD+ availability changes over a lifespan. Together, sirtuins, PARPs, and CD38 form a trio of enzyme systems whose combined appetite for NAD+ helps explain why maintaining the pool is such a recurring theme in the literature.
One of the most persistent observations in this field is that NAD+ levels appear to decline with age across a range of tissues in research models, from cultured cells to animal studies. This decline is widely discussed, and the proposed explanations generally fall into two complementary categories: reduced production and increased consumption.
On the consumption side, the enzymes described above are implicated. Rising CD38 activity in older tissues is one frequently cited contributor, as is chronic PARP activation in response to accumulating DNA damage. Both processes draw down NAD+ faster than it can be replenished. On the production side, researchers have examined whether the salvage and biosynthetic machinery that regenerates NAD+ becomes less efficient over time, tilting the balance further toward depletion.
It is important to frame this carefully. The decline of NAD+ with age is an active and evolving area of investigation, studied in cell and animal systems, and the molecular details are still being worked out. The observation has motivated a great deal of research into whether supporting NAD+ availability affects cellular function in these models — but that work remains preclinical and mechanistic. None of it establishes any human health benefit, and within the research context Alluvia Peptides serves, NAD+ is studied as a molecule of biological interest, not used as a product for people.
Because NAD+ touches so many fundamental processes, it appears across a wide span of laboratory research. The themes below are the ones most commonly encountered in the scientific literature, all conducted in cell cultures, isolated systems, or animal models rather than as human interventions.
Across all of these areas, the consistent thread is mechanistic curiosity: researchers are mapping how a single coenzyme influences the machinery of the cell. The findings inform hypotheses and future studies; they are not statements about human outcomes.
Cells do not synthesise all of their NAD+ from scratch every time they need it. Instead, they rely heavily on recycling, and the dominant route in mammalian cells is the NAD+ salvage pathway. When NAD+-consuming enzymes such as sirtuins, PARPs, and CD38 break the molecule down, one of the products is nicotinamide. The salvage pathway captures this nicotinamide and converts it back toward NAD+, first into nicotinamide mononucleotide (NMN) by the enzyme NAMPT, and then into NAD+ itself. This loop allows the cell to reuse its nicotinamide rather than constantly importing or building new material, and NAMPT is widely regarded as the rate-limiting checkpoint of the process.
Several precursors feed into NAD+ biosynthesis and are frequently studied alongside it:
These precursors are studied as research tools for raising NAD+ availability in experimental systems, and they are common reference points in the longevity literature. As with NAD+ itself, any such material handled by a laboratory is for research use only.
The table below summarises the core properties most relevant to laboratory work, formatted for quick reference.
| Property | Detail |
|---|---|
| Full name | Nicotinamide adenine dinucleotide |
| Classification | Coenzyme / dinucleotide (electron carrier and enzyme cofactor) |
| Is it a peptide? | No — it contains no amino acids or peptide bonds |
| Redox partner | NADH (the reduced form) |
| Redox role | Oxidising agent in glycolysis, the TCA cycle, and oxidative phosphorylation |
| Key enzyme partners | Sirtuins, PARPs, and CD38 (NAD+-consuming signalling enzymes) |
| Biosynthesis | Salvage pathway (via nicotinamide → NMN → NAD+) plus precursor routes |
| Common precursors | NMN, NR (nicotinamide riboside), niacin |
| Typical research form | Lyophilised (freeze-dried) powder for reconstitution |
| Laboratory storage | Cold-chain; long-term storage frozen, protected from light and moisture |
| Quality verification | HPLC purity testing with a Certificate of Analysis (COA) per batch |
| Designation | Research use only — not for human or animal consumption |
Research-grade NAD+ is typically supplied as a lyophilised (freeze-dried) powder, a format chosen because it maximises stability during shipping and storage. NAD+ in solution is considerably less stable than in dry form, so the powder is generally kept sealed and frozen until a study calls for it. As a practical matter, laboratories handling NAD+ pay attention to a few recurring factors.
Temperature is the dominant concern. The dry powder is best held under cold-chain conditions, with long-term storage in a freezer and protection from repeated temperature swings. Moisture and light are the next considerations: NAD+ is hygroscopic and can degrade with exposure to humidity, so vials are kept sealed and allowed to reach room temperature before opening to avoid condensation drawing water into the powder.
Reconstitution — dissolving the powder into a suitable solvent for experimental use — is performed according to the requirements of the specific assay, and the resulting solution is treated as far more perishable than the powder. Many laboratories prepare working solutions fresh, use them promptly, and minimise freeze-thaw cycles, since each cycle can degrade the molecule. Aliquoting a stock solution into single-use portions is a common strategy to avoid repeatedly thawing and refreezing the same material. Throughout, NAD+ is handled strictly as a laboratory reagent, with appropriate personal protective equipment and documentation, and never administered to humans or animals.
In research, the value of any compound depends on knowing exactly what is in the vial — and at what purity. Impurities, degradation products, or moisture can confound an experiment and undermine reproducibility, so rigorous quality verification is non-negotiable for research-grade NAD+.
The cornerstone of that verification is purity testing by HPLC (high-performance liquid chromatography), which separates the components of a sample and quantifies how much of it is the intended molecule versus contaminants or breakdown products. A high stated purity (commonly expressed as a percentage by HPLC) indicates that the great majority of the material is genuine NAD+. Complementary analytical methods, such as mass spectrometry, may be used to confirm the molecule's identity by its molecular mass.
These results are documented in a Certificate of Analysis (COA) — a batch-specific record summarising the identity, purity, and test methods for a given lot of material. A COA is what allows a researcher to trust that the reagent meets specification, and it provides the traceability needed for reproducible, well-documented work. Reputable suppliers issue a COA for every batch, so that each lot can be verified independently rather than relying on a one-time certificate. When sourcing NAD+ for the laboratory, the presence of current, batch-specific analytical documentation is among the most important markers of quality.
No. NAD+ is a coenzyme — specifically the oxidised form of nicotinamide adenine dinucleotide, a dinucleotide built from an adenine nucleotide and a nicotinamide nucleotide joined through phosphate groups. Peptides are chains of amino acids linked by peptide bonds; NAD+ contains neither amino acids nor peptide bonds. It is supplied in the longevity and metabolic-research catalogue alongside peptides, but chemically it belongs to a different class entirely.
The plus sign denotes the positive charge carried on the nicotinamide ring in the oxidised state. NAD+ is the oxidised, electron-accepting form; when it gains a pair of electrons (as a hydride), it becomes the reduced form, NADH. Writing it as "NAD+" is a way of specifying which member of the redox pair is being referred to.
They are the two forms of the same redox couple. NAD+ is the oxidised form that accepts electrons during metabolic reactions, and NADH is the reduced form that carries those electrons to the electron transport chain. Cells continuously interconvert the two, and the NAD+/NADH ratio is often used by researchers as an indicator of a cell's metabolic state.
Precursors are upstream building blocks that cells convert into NAD+. NMN (nicotinamide mononucleotide) is one enzymatic step from NAD+ in the salvage pathway; NR (nicotinamide riboside) is converted to NMN and then onward to NAD+; and niacin feeds NAD+ production through a separate pathway. In research, these compounds are studied as tools for raising NAD+ availability in experimental systems.
As a lyophilised powder under cold-chain conditions — sealed, frozen for long-term storage, and protected from light and moisture. Once reconstituted into solution, NAD+ is much less stable and is generally used promptly, with freeze-thaw cycles minimised (often by aliquoting). It should always be handled as a laboratory reagent for research use only, never administered to humans or animals.
For laboratories sourcing NAD+ as a research reagent, Alluvia Peptides supplies high-purity, research-grade material intended strictly for in-vitro and preclinical study. Each batch is backed by HPLC purity testing and a Certificate of Analysis (COA), and material is dispatched under cold-chain handling to preserve stability in transit. This emphasis on batch-level verification and proper temperature control is what makes a reagent suitable for reproducible scientific work.
Explore the product and related research compounds here:
Research use only — not for human consumption. The information in this article is provided for educational and laboratory-research purposes only. NAD+ and all related compounds described here are intended exclusively for in-vitro and laboratory research and are not for human or animal consumption, and not for diagnostic, therapeutic, cosmetic, or any in-vivo use in people. Nothing here is medical advice or a claim of any health benefit. All effects discussed refer to findings in research models and the scientific literature. Always follow applicable laws, institutional guidelines, and good laboratory practice when handling research materials.